AboutProductMarketInvestor RelationsContact

Cold Sore Market

With Lipivir®, Devirex possesses the only preventive solution against cold sores

The Market

  • In the examined markets, 33% of the population have at least 1 herpes outbreak/year*
  • 10% of the population have between 3-20 outbreaks*

Positioning of lipivir®

  • Lipivir® in the prevention and personal care segment
  • High accessibility as it is not a pharmaceutical product. "Direct to customer" possible without constraints (multi-channel)
  • Vegan and cruelty-free product

Unique selling points

  • Preventive use averts outbreaks of cold sores (HSV-1)**
  • Preventive use averts long acute treatments*** (7-8 days)
  • 9 out of 10 outbreaks are prevented
  • Lipivir® promotes well-being and strengthens the confidence and self-assurance of those affected
* Detailed analyses are available and were carried out by Devirex in 2017 with renowned research institutes ** Herpes simplex virus, HSV-1 *** Clinical study at the University Hospital of Zurich (88% effectiveness)
Devirex AG Rothusstrasse 7 CH-6331 Hünenberg +41 41 758 00 00 info@devirex.ch